Nephrocare Health Services
- P/E
- 148.53
Key Fundamentals
MicrocapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 15.30%
- Debt to Equity
- 0.07
- EPS (TTM)
- ₹4.19
- Book Value
- ₹111.03
- Market Cap
- —
- P/E (TTM)
- 148.53
- P/B
- 5.61
- ROE
- 8.83%
- Dividend Yield
- 0.00%
- EBITDA
- ₹252 Cr
- 52W High
- ₹781.50
- 52W Low
- ₹446.00
- Day Range
- ₹585.50 – ₹635.20
- Volume
- 5,11,013
Peer Comparison
Healthcare › Healthcare Services › Healthcare Service Provider
| ₹2,029.40 | 62.75 | ₹32,036 Cr | 13.58 | 0.26% | 22.30% | 28.00% | ₹2,891 Cr | ₹545 Cr | |
| ₹1,424.60 | 78.15 | ₹14,588 Cr | 15.33 | 0.14% | 18.30% | 20.50% | ₹857 Cr | ₹187 Cr | |
| ₹581.25 | 59.74 | ₹11,437 Cr | 8.03 | 0.88% | 13.60% | 17.80% | ₹1,710 Cr | ₹203 Cr | |
| ₹495.50 | 44.72 | ₹7,723 Cr | 14.25 | 2.90% | 28.40% | 35.40% | ₹876 Cr | ₹176 Cr | |
| Nephrocare Health Services (this company) | ₹622.35 | 148.53 | ₹5,903 Cr | 5.61 | 0.00% | 8.83% | 15.30% | ₹1,053 Cr | ₹85 Cr |
| ₹333.05 | 48.41 | ₹1,717 Cr | 7.08 | 0.15% | 14.20% | 17.30% | ₹325 Cr | ₹35 Cr | |
| ₹483.05 | 15.84 | ₹1,571 Cr | 1.51 | 0.41% | 10.90% | 12.70% | ₹726 Cr | ₹98 Cr | |
| Median 7 companies | ₹581.25 | 59.74 | ₹7,723 Cr | 8.03 | 0.26% | 14.20% | 17.80% | ₹876 Cr | ₹176 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 47
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 29
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 83
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 67
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 40
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 36
- Poor
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 162% CAGR over last 5 years
Weaknesses
4- Stock is trading at 5.73 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Company's cost of borrowing seems high
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 6 | 5 | 8 |
| Oscillators | Bullish | 1 | 5 | 3 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Neutral
Key readings
- RSI (14)
- 43.32
- Neutral
- MACD (12,26,9)
- −12.80
- Bullish
- SMA (50)
- 670.30
- Bearish
- SMA (200)
- 619.93
- Bullish
As of
Analyst Rating
3 of 3 analysts rate Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +28.42% |
|---|---|
| 3Y | +31.73% |
| 1Y | +32.14% |
Net profit
| 5Y | +138.40% |
|---|---|
| 3Y | Turned to profit |
| 1Y | +14.93% |
Operating cash flow
| 5Y | +48.74% |
|---|---|
| 3Y | +176.69% |
| 1Y | +72.59% |
Operating margin· change in pp
| 5Y | +9.58 pp |
|---|---|
| 3Y | +11.31 pp |
| 1Y | +0.43 pp |
Trailing twelve months: Fewer than eight quarters are reported, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2021 | ₹286 Cr |
|---|---|
| Mar 2022 | ₹318 Cr |
| Mar 2023 | ₹437 Cr |
| Mar 2024 | ₹566 Cr |
| Mar 2025 | ₹756 Cr |
| Mar 2026 | ₹999 Cr |
Net profit by year
| Mar 2021 | ₹1.00 Cr |
|---|---|
| Mar 2022 | −₹21.00 Cr |
| Mar 2023 | −₹12.00 Cr |
| Mar 2024 | ₹35.00 Cr |
| Mar 2025 | ₹67.00 Cr |
| Mar 2026 | ₹77.00 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Nephrocare Health Services (NephroPlus) is a healthcare services company with a market cap of ₹6,798 Cr trading at a PE of 89.4x. The company has delivered strong revenue growth of 32% CAGR over 3 years and profit growth of 162% CAGR over 5 years, but carries a relatively low ROE of ~10% over 3 years and trades at 6.15x book value with zero dividend payout.
- Exceptional profit growth of 162% CAGR over the last 5 years indicates strong operating leverage and scalability in the dialysis services business
- Consistent revenue growth of 32% CAGR over 3 years and 28% over 5 years demonstrates sustained demand for nephrology services
- Company is almost debt-free, significantly reducing financial risk and interest burden on the balance sheet
- Active debt reduction demonstrates disciplined capital allocation and strengthening of the balance sheet over time
- TTM sales growth of 32% shows continued momentum in the most recent period with no signs of deceleration from the 3-year trend
- Operating in the chronic kidney disease treatment space which has structural tailwinds from rising diabetes and hypertension prevalence in India
- TTM profit growth of 12% shows the company remains profitable and growing even as it scales, though at a slower pace than historical averages
- 3-year average ROE of only 10% is modest for a company trading at such premium valuations, suggesting capital is not being deployed efficiently enough to justify the price
- Zero dividend yield despite repeated profitability indicates shareholders receive no income return, with all value dependent on capital appreciation
- Price-to-book ratio of 6.15x means investors are paying a steep premium over the company's net asset value
- TTM profit growth has decelerated sharply to 12% compared to 103% CAGR over 3 years, suggesting growth normalization or margin pressure
- Company's cost of borrowing appears high, which could erode returns if any future debt is taken on for expansion
- Last year ROE of 9% is below the 3-year average of 10%, indicating a declining trend in return on equity rather than improvement
- With no stock CAGR data available across any time period, there is limited price history transparency for investors to assess historical shareholder returns
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: A quiet period for Nephrocare Health Services with no material positive or negative catalysts. The Rs 70 crore block trade suggests institutional interest but direction is unclear without knowing buyer/seller intent. Investors should watch the Q1FY27 results on Aug 12 for growth trajectory and margin trends in the dialysis services business.
- Rs 70 Cr block trade executed Jul 9
A block trade worth Rs 70 crore was executed on NSE/BSE for approximately 11 lakh shares at Rs 636.36 per share, indicating significant large-scale institutional activity.
- Q1FY27 earnings call Aug 12 Jul 24
Nephrocare has scheduled its Q1FY27 earnings conference call for August 12, 2026 to discuss unaudited standalone and consolidated results for the quarter ended June 30, 2026.
- 17th AGM on Aug 12 Jul 17
Nephrocare will hold its 17th AGM on August 12, 2026 via video conferencing, with remote e-voting open from August 8 to August 11.
Quarterly Results
₹ Cr| Particulars | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 | 303 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 | — |
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 | — |
| OPM % | 22% | 23% | 21% | 26% | 23% | 19% | 21% | — |
| Other Income | 5 | 4 | 7 | 4 | 3 | 12 | 7 | — |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 | 3 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 | 28 |
| PBT | 26 | 30 | 29 | −1 | 36 | 33 | 41 | 40 |
| Tax % | 24% | 17% | 17% | 1427% | 11% | 9% | 22% | 17% |
| Net Profit | 20 | 25 | 24 | −9 | 32 | 30 | 32 | 34 |
| EPS (₹) | 96.5 | 119 | 13.1 | −5.24 | 3.21 | 3.03 | 3.19 | — |
Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 286 | 318 | 437 | 566 | 756 | 999 | 1,053 |
| Expenses | 248 | 302 | 389 | 465 | 589 | 774 | 817 |
| Operating Profit | 37 | 16 | 49 | 101 | 167 | 225 | 236 |
| OPM % | 13% | 5% | 11% | 18% | 22% | 23% | 22% |
| Other Income | 5 | 10 | 6 | 8 | 14 | 24.51 | 26 |
| Interest | 7 | 10 | 16 | 20 | 21 | 60 | 56 |
| Depreciation | 34 | 42 | 47 | 56 | 72 | 91 | 96 |
| PBT | 1 | −27 | −9 | 33 | 87 | 97 | 110 |
| Tax % | 31% | −21% | 37% | −6% | 23% | 21% | — |
| Net Profit | 1 | −21 | −12 | 35 | 67 | 77 | 85 |
| EPS (₹) | 3.4 | −107 | −58.69 | 170 | 322 | 7.66 | 4.19 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 |
| Reserves | 245 | 391 | 384 | 409 | 579 | 1,096 |
| Borrowings | 140 | 119 | 200 | 271 | 261 | 80 |
| Other Liabilities | 42 | 59 | 81 | 124 | 153 | 271 |
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1,467 |
| Fixed Assets | 192 | 205 | 239 | 356 | 396 | 517 |
| CWIP | 2 | 43 | 34 | 1 | 6 | 6 |
| Investments | 0 | 0 | 0 | 0 | 51 | 178 |
| Other Assets | 234 | 322 | 393 | 449 | 542 | 767 |
| Total Assets | 428 | 571 | 666 | 806 | 994 | 1,467 |
Cash Flow
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 32 | 14 | 11 | 72 | 135 | 233 |
| Investing | −62 | −130 | −76 | −52 | −125 | −392 |
| Financing | 36 | 121 | 60 | 27 | 54 | 157 |
| Net Cash Flow | 5 | 6 | −4 | 47 | 65 | −2 |
| Free Cash Flow | −29 | −64 | −62 | −8 | 35 | 113 |
| CFO/OP | 49 | 119 | 14 | 80 | 82 | 116 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 101 | 123 | 132 | 131 | 129 | 116 |
| Inventory Days | 65 | 50 | 67 | — | — | — |
| Days Payable | 56 | 70 | 63 | — | — | — |
| Cash Conversion Cycle | 110 | 103 | 137 | 131 | 129 | 116 |
| Working Capital Days | 26 | 55 | 19 | 56 | 27 | 42 |
| ROCE % | — | −4% | 1% | 8% | 14% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nephrocare Health Services insights
61 extracted metrics across FY21–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Concall · Feb 2026Transcript PPT Recording
- 20 Jun 2025
- 22 Mar 2024
- 30 Dec 2022
- General announcements 3 Nov 2026
Frequently Asked Questions about Nephrocare Health Services
What does Nephrocare Health Services Ltd do?
Where is Nephrocare Health Services Ltd (NEPHROPLUS) listed?
Which sector does Nephrocare Health Services Ltd belong to?
What is the PE ratio of Nephrocare Health Services Ltd?
What is the 52-week high and low of Nephrocare Health Services Ltd?
What is the Return on Equity (ROE) of Nephrocare Health Services Ltd?
Company Information
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEPHROPLUS.md for Nephrocare Health Services Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.